

## Adjuvant/Curative/Neo-adjuvant Gastroesophageal Cancer Regimens

The following table lists the evidence-informed regimens (both IV and non-IV) for gastroesophageal cancer used in the adjuvant/curative/neo-adjuvant setting. It is expected that the prescribing oncologist will select the regimen from the list of evidence-informed regimens that is most appropriate for their patient taking account of a variety of disease-specific and patient-related factors.

**Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.**

<b>Gastroesophageal Cancer</b>	
<b>Regimen Code</b>	<b>Regimen Abstract</b>
CISPETOP(3D)	CISplatin 25 mg/m <sup>2</sup> IV days 1-3; Etoposide 100 mg/m <sup>2</sup> IV days 1-3. Q21 days <i>For Small Cell Carcinoma</i>
CISPFU	CISplatin 80 mg/m <sup>2</sup> IV day 1; Fluorouracil 800 mg/m <sup>2</sup> /day CIV over 24 hours days 1-5. Q21 – Q28 days
CISPFU(RT)	Weeks 1 & 5 concurrent with radiation: CISplatin 75 mg/m <sup>2</sup> IV day 1; Fluorouracil 1000 mg/m <sup>2</sup> /day CIV over 24 hours days 1-4. THEN post radiation Q21 days for 4 cycles total  <i>Alternative Schedule:</i> Weeks 1 & 5 concurrent with radiation: CISplatin 25 mg/m <sup>2</sup> IV days 1-3 OR days 2-4; Fluorouracil 1000 mg/m <sup>2</sup> /day CIV over 24 hours days 1-4. THEN post radiation Q21 days for 4 cycles total  <i>Alternative Schedule:</i> Weeks 1 & 5 concurrent with radiation: CISplatin 15 mg/m <sup>2</sup> IV days 1-5; Fluorouracil 1000 mg/m <sup>2</sup> /day CIV over 24 hours days 1-4. THEN post radiation Q21 days for 4 cycles total
CRBPETOP	CARBOplatin AUC 5 IV day 1; Etoposide 100 mg/m <sup>2</sup> IV days 1-3. Q21 days <i>For Small Cell Carcinoma</i>

## Gastroesophageal Cancer

Regimen Code	Regimen Abstract
CRBPFU	CARBOplatin AUC 4-5 IV day 1; Fluorouracil 1000 mg/m <sup>2</sup> /day CIV days 1-4. Q21 - Q28 days
CRBPPACL(RT)	CARBOplatin AUC 2, days 1, 8, 15, 22, 29; PACLitaxel 50 mg/m <sup>2</sup> , days 1, 8, 15, 22, 29 Concurrent with radiation
ECARBOF	EPIrubicin 50 mg/m <sup>2</sup> IV day 1; CARBOplatin AUC 5 day 1; Fluorouracil 200 mg/m <sup>2</sup> /day CIV over 24 hours days 1-21. Q21 days
ECF	EPIrubicin 50 mg/m <sup>2</sup> IV day 1; CISplatin 60 mg/m <sup>2</sup> IV day 1; Fluorouracil 200 mg/m <sup>2</sup> /day CIV over 24 hours days 1-21. Q21 days
FULCVR(RT-GAST)	<p><i>Standard Schedule:</i></p> <p><u>Cycle 1:</u> Fluorouracil 425 mg/m<sup>2</sup> IV days 1-5; Leucovorin 20 mg/m<sup>2</sup> IV days 1-5. Q28 days</p> <p><u>Cycle 2:</u> Fluorouracil 400 mg/m<sup>2</sup> IV days 1-4; Leucovorin 20 mg/m<sup>2</sup> IV days 1-4. Q28 days</p> <p>Concurrent with radiation</p> <p><u>Cycle 3:</u> Fluorouracil 400 mg/m<sup>2</sup> IV days 1-3; Leucovorin 20 mg/m<sup>2</sup> IV days 1-3. Q28 days</p> <p>Concurrent with radiation</p> <p><u>Cycles 4, 5:</u> Fluorouracil 425 mg/m<sup>2</sup> IV days 1-5; Leucovorin 20 mg/m<sup>2</sup> IV days 1-5. Q28 days</p> <p><i>Alternative Schedule #1:</i></p> <p><u>Cycle 1:</u> Fluorouracil 400 mg/m<sup>2</sup> IV days 1, 15; Leucovorin 400 mg/m<sup>2</sup> IV days 1, 15; THEN Fluorouracil 2400 mg/m<sup>2</sup> CIV over 46 hours days 1, 15. Q28 days</p> <p><u>Cycle 2:</u> Fluorouracil 225 mg/m<sup>2</sup> CIV over 24 hours daily concurrent with radiotherapy</p> <p><u>Cycle 3, 4:</u> Fluorouracil 400 mg/m<sup>2</sup> IV days 1, 15; Leucovorin 400 mg/m<sup>2</sup> IV days 1, 15;</p>

## Gastroesophageal Cancer

Regimen Code	Regimen Abstract
	<p>THEN Fluorouracil 2400 mg/m<sup>2</sup> CIV over 46 hours days 1, 15. Q28 days</p> <p><i>Alternative Schedule #2:</i></p> <p><u>Cycle 1:</u> Fluorouracil 425 mg/m<sup>2</sup> IV days 1-5; Leucovorin 20 mg/m<sup>2</sup> IV days 1-5. Q28 days</p> <p><u>Cycle 2:</u> Fluorouracil 200 mg/m<sup>2</sup> CIV over 24 hours daily concurrent with radiotherapy</p> <p><u>Cycles 3, 4:</u> Fluorouracil 425 mg/m<sup>2</sup> IV days 1-5; Leucovorin 20 mg/m<sup>2</sup> IV days 1-5. Q28 days</p>
CAPECISP	<p><b>Capecitabine 1000 mg/m<sup>2</sup> PO BID days 1-14 – Not currently publicly funded for this regimen and intent;</b> CISplatin 60-80 mg/m<sup>2</sup> IV day 1. Q21 days</p>
CAPECISP(RT)	<p><u>Cycles 1 &amp; 2:</u> <b>Capecitabine 1000 mg/m<sup>2</sup> PO BID days 1-14 – Not currently publicly funded for this regimen and intent;</b> CISplatin 60 mg/m<sup>2</sup> IV day 1. Q21 days</p> <p><u>Cycle 3:</u> <b>Capecitabine 825 mg/m<sup>2</sup> PO BID either on days of radiation (5 days/week), or continuously (7 days/week) during radiotherapy – Not currently publicly funded for this regimen and intent;</b></p> <p><u>Cycles 4 &amp; 5:</u> <b>Capecitabine 1000 mg/m<sup>2</sup> PO BID days 1-14 – Not currently publicly funded for this regimen and intent;</b> CISplatin 60 mg/m<sup>2</sup> IV day 1. Q21 days</p>
CAPE(RT)	<p><b>Capecitabine is not currently publicly funded for this regimen and intent;</b></p> <p><u>Cycle 1:</u> Capecitabine 1000 mg/m<sup>2</sup> PO BID days 1-14 Q28 days</p> <p><u>Cycle 2:</u> Capecitabine 825 mg/m<sup>2</sup> PO BID either on days of radiation (5 days/week), or continuously (7 days/week) during radiotherapy</p> <p><u>Cycle 3:</u> Capecitabine 1000 mg/m<sup>2</sup> PO BID days 1-14 Q28 days</p> <p><u>Cycle 4:</u> Capecitabine 1000 mg/m<sup>2</sup> PO BID days 1-14 Q28 days</p>

## Gastroesophageal Cancer

Regimen Code	Regimen Abstract
ECARBOX	EPIrubicin 50 mg/m <sup>2</sup> IV day 1; CARBOplatin AUC 5 IV day 1; <b>Capecitabine 625 mg/m<sup>2</sup> PO BID days 1-21 – Not currently publicly funded for this regimen and intent</b> Q21 days
ECX	EPIrubicin 50 mg/m <sup>2</sup> IV day 1; CISplatin 60 mg/m <sup>2</sup> IV day 1; <b>Capecitabine 625 mg/m<sup>2</sup> PO BID days 1-21 – Not currently publicly funded for this regimen and intent</b> Q21 days
FLODOCE	DOCEtaxel 50 mg/m <sup>2</sup> IV day 1; <b>Oxaliplatin 85 mg/m<sup>2</sup> IV day 1 – Not currently publicly funded for this regimen and intent;</b> Leucovorin 200* mg/m <sup>2</sup> IV day 1; Fluorouracil 2600 mg/m <sup>2</sup> CIV over 24 hours day 1. Q14 days  <i>Note: *the racemic mixture of leucovorin was used in the FLOT4 trial by Al-Batran SE et al.</i>
MFOLFOX6	<b>Oxaliplatin 85 mg/m<sup>2</sup> IV day 1 – Not currently publicly funded for this regimen and intent;</b> Leucovorin 400 mg/m <sup>2</sup> IV day 1; Fluorouracil 400 mg/m <sup>2</sup> IV day 1; THEN Fluorouracil 2400 mg/m <sup>2</sup> CIV over 46 hrs day 1. Q14 days
XELOX	<b>Capecitabine 1000 mg/m<sup>2</sup> PO BID days 1-14 – Not currently publicly funded for this regimen and intent;</b> <b>Oxaliplatin 130 mg/m<sup>2</sup> IV day 1 – Not currently publicly funded for this regimen and intent.</b> <b>Q21 days</b>

Last Updated: November 2017